-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 24, Qilu Pharmaceuticals submitted a new class 4 generic drug Peropani tablet market application entered the "in the approval" stage, is expected to be officially approved as the first imitation in the near future.
pyrupani is a vascular endotebrate growth factors (VEGFR) 1, 2 and 3, plate plate plate derived growth factors (plors) α and β, fibroblast growth factors (FGFR) -1 and -3, cytokines affected by A multi-target tyrosine kinase inhibitor induced by the body (Kit), the leucin-mediate-2-induced T-cell kinase (Itk), the white blood cell-specific protein tyrosine kinase (LcK), and the trans-membrane glycoprotein-like kinase (c-Fms).
approved by the FDA in October 2009 and has been approved for allergies such as renal cell carcinoma and soft tissue sarcoma.
in February 2017, the drug was approved in China for the treatment of renal cell carcinoma, and was subsequently successfully included in The Health Care Category B list in the 2018 health care negotiations.
originally a GSK product, but was packaged and sent away in 2014 in an asset replacement deal between GSK and Novarlor.
sales of the drug in 2019 were $755 million.
Renal cell carcinoma (RCC) is a common malignant tumor in the world, the morbidity and mortality rate accounts for about 2%-3% of systemic tumors, in the urinary system malignant tumors, the incidence rate is second only to bladder cancer, and is increasing year by year.
recent years, targeted drugs have made great progress in the treatment of advanced kidney cancer, and since 2005 several drugs have been approved for market and become the standard treatment for advanced kidney cancer.
The current incidence of RCC in China is 4.7 per 100,000 men, about 3 per 100,000 women, the annual incidence of kidney cancer increased by about 2.5%, has been approved by the National Drug Administration to treat RCC drugs including Shonithini (Pfizer), Sorafeni (Bayer), Evimos (Novarma), Acytini (Pfizer), Anrodini (ZhengdaTian) and Shonini (Pfizer).
.
